UTHR Form 144: Martine Rothblatt proposes 4,000-share sale on NASDAQ

Rhea-AI Filing Summary

UNITED THERAPEUTICS (UTHR) filed a Form 144 disclosing a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,778,788.40, slated for 10/10/2025 on NASDAQ. The filing shows the shares were originally acquired on 03/15/2016 as executive deferred compensation from Martine Rothblatt, with 294,000 shares acquired in that transaction and payment made via vested options exercised with common shares. The notice also lists multiple recent sales by the same person totaling 88,000 shares sold across dates from 09/09/2025 to 10/09/2025, with individual daily proceeds ranging roughly from $1.59M to $1.81M. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1 language where applicable.

Insights

Equity Capital Markets Analyst

Insider is actively monetizing a large block of shares over several weeks.

The filing shows a planned sale of 4,000 shares on 10/10/2025

and a series of prior daily sales totaling 88,000 shares between 09/09/2025 and 10/09/2025. Regular, incremental sales via a broker are typical for liquidity management and can limit immediate market impact while converting equity to cash.

Key dependencies include daily market liquidity and execution prices; watch short-term volume and price moves around the listed sale dates over the next few trading days.

Corporate Governance Analyst

Disclosure aligns with Rule 144 requirements and shows prior option-related acquisition.

The securities were acquired on 03/15/2016 under an executive deferred compensation arrangement and were exercised and paid using common shares, as disclosed. That acquisition method is relevant to holding-period and resale eligibility under Rule 144.

The filer includes the customary representation about lacking undisclosed material information; investors may note continuing scheduled disposals but should rely on public disclosures for material company events in the near term.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	TD SECURITIES (USA) LLC 125 PARK AVE, 20th Floor NEW YORK NY 10017	4000	1778788.40	45230000	10/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/23/2025	4000	1672592.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/24/2025	4000	1736488.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/25/2025	4000	1723739.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/26/2025	4000	1712891.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/29/2025	4000	1702526.76
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/30/2025	4000	1691357.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/01/2025	4000	1701796.53
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/02/2025	4000	1739525.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/03/2025	4000	1784847.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/06/2025	4000	1798765.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/07/2025	4000	1807320.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/08/2025	4000	1803449.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/09/2025	4000	1795655.20

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did UNITED THERAPEUTICS (UTHR) disclose in this Form 144?

The filing discloses a proposed sale of 4,000 common shares valued at $1,778,788.40 for sale on 10/10/2025 via TD Securities (USA) LLC on NASDAQ.

Who is the seller named in the Form 144 for UTHR?

The seller is Martine Rothblatt, who acquired the disclosed shares on 03/15/2016 through an executive deferred compensation arrangement.

How many shares has the insider recently sold?

The filing lists multiple sales totaling 88,000 shares sold between 09/09/2025 and 10/09/2025, with daily gross proceeds ranging roughly from $1.59M to $1.81M.

Does the filing indicate any undisclosed material information?

By signing the notice, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

How were the shares originally paid for or acquired?

The shares were acquired on 03/15/2016 via executive deferred compensation, with payment made through exercising vested options and using common shares.